8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Feb 13, 2026·SEC
Centessa Pharmaceuticals plc(CNTA)Earnings, Financials & Key Ratios
CNTA•NASDAQ
Price updated Jun 11, 2026
AboutCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.Show more
- Revenue$15M
- EBITDA-$208M-3.8%
- Net Income-$198M+16.2%
- EPS (Diluted)-1.46+29.1%
- Gross Margin100%
- EBITDA Margin-1384.61%
- Operating Margin-1384.61%
- Net Margin-1316.88%
- ROE-42.55%+42.4%
- ROIC-51.18%+44.3%
- Debt/Equity0.01-95.1%
- Interest Coverage-18.12+17.9%
CNTA Key Insights
Centessa Pharmaceuticals plc (CNTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 79.3% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 18.6% in last year
- ✗Expensive at 10.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CNTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CNTA Price & Volume
Centessa Pharmaceuticals plc (CNTA) stock price & volume — 10-year historical chart
Loading chart...
CNTA Growth Metrics
Centessa Pharmaceuticals plc (CNTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.66%
Return on Capital
10 Years-105.5%
5 Years-59.2%
3 Years-43.58%
Last Year-35.71%
CNTA Recent Earnings
Centessa Pharmaceuticals plc (CNTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 5, 2026EPS
$0.52
Est $0.38
-36.8%
Revenue
—
Q2 2026
Mar 31, 2026EPS
$0.48
Est $0.37
-29.2%
Revenue
—
Est $1M
Q4 2025
Nov 5, 2025EPS
$0.41
Est $0.39
-5.1%
Revenue
—
Est $767,000
Q3 2025
Aug 12, 2025EPS
$0.38
Est $0.35
-8.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.52vs $0.38-36.8% | — |
| Q2 2026 | Mar 31, 2026 | $0.48vs $0.37-29.2% | —vs $1M |
| Q4 2025 | Nov 5, 2025 | $0.41vs $0.39-5.1% | —vs $767,000 |
| Q3 2025 | Aug 12, 2025 | $0.38vs $0.35-8.6% | — |
Based on last 12 quarters of dataView full earnings history →
CNTA Peer Comparison
Centessa Pharmaceuticals plc (CNTA) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 VERA | 2.41B | 33.65 | -7.22 | -74.86% | 0.13 | |||
 TPST | 5.55M | 1.25 | -0.20 | -7.3% | 1.22 | |||
 ALNY | 38.61B | 289.39 | 124.20 | 65.19% | 13.46% | 98.29% | 1.62 | |
 PTGX | 7.06B | 109.79 | -53.56 | -89.41% | -6.48% | -17.76% | 0.02 |
Compare CNTA vs Peers
Centessa Pharmaceuticals plc (CNTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CNTA Income Statement
Centessa Pharmaceuticals plc (CNTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 6.85M | 0 | 15M | 0 |
Revenue Growth % | - | - | - | - | -100% | - | -100% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 238.6K |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 6.85M▲ 0% | 0▼ 100.0% | 15M▲ 0% | -238.6K▲ 0% |
Gross Margin % | - | - | - | 100% | - | 100% | - |
Gross Profit Growth % | - | - | - | - | -100% | - | - |
Operating Expenses | 10.44M | 374.87M | 212.26M | 178.14M | 201.06M | 222.69M | 256.69M |
OpEx % of Revenue | - | - | - | 2599.39% | - | 1484.61% | - |
Selling, General & Admin | 1.14M | 43.01M | 55.2M | 53.73M | 50.81M | 50.47M | 58.02M |
SG&A % of Revenue | - | - | - | 784.05% | - | 336.45% | - |
Research & Development | 9.3M | 96.32M | 155.08M | 124.41M | 150.24M | 172.22M | 198.67M |
R&D % of Revenue | - | - | - | 1815.34% | - | 1148.16% | - |
Other Operating Expenses | 0 | 235.54M | 1.98M | 0 | 0 | 0 | 0 |
Operating Income | -10.44M▲ 0% | -374.87M▼ 3490.7% | -212.26M▲ 43.4% | -171.28M▲ 19.3% | -201.06M▼ 17.4% | -207.69M▼ 3.3% | -256.69M▲ 0% |
Operating Margin % | - | - | - | -2499.39% | - | -1384.61% | - |
Operating Income Growth % | - | -3490.68% | 43.38% | 19.31% | -17.38% | -3.3% | - |
EBITDA | -10.29M | -374.83M | -212.13M | -170.47M | -200.11M | -207.69M | -256.67M |
EBITDA Margin % | - | - | - | -2487.57% | - | -1384.61% | - |
EBITDA Growth % | - | -3544.46% | 43.41% | 19.64% | -17.39% | -3.79% | -31.74% |
D&A (Non-Cash Add-back) | 0 | 34K | 131K | 810K | 942K | 0 | 21.6K |
EBIT | -10.29M | -139.33M | -209.68M | -166.24M | -222.82M | -207.69M | -265.47M |
Net Interest Income | -378K | -2.55M | -7.03M | 570K | 3.93M | 9.07M | 6.46M |
Interest Income | 0 | 0 | 244K | 10.48M | 14.02M | 20.53M | 17.77M |
Interest Expense | 378K | 2.55M | 7.28M | 9.91M | 10.09M | 11.46M | 11.31M |
Other Income/Expense | -223K | -6.92M | -4.69M | -4.86M | -31.86M | 11.98M | 7.32M |
Pretax Income | -10.66M▲ 0% | -381.79M▼ 3480.5% | -216.95M▲ 43.2% | -176.14M▲ 18.8% | -232.91M▼ 32.2% | -195.71M▲ 16.0% | -249.37M▲ 0% |
Pretax Margin % | - | - | - | -2570.28% | - | -1304.75% | - |
Income Tax | 0 | 114K | -747K | -25.06M | 2.84M | 1.82M | 1.27M |
Effective Tax Rate % | 0% | -0.03% | 0.34% | 14.22% | -1.22% | -0.93% | -0.51% |
Net Income | -10.66M▲ 0% | -381.9M▼ 3481.5% | -216.21M▲ 43.4% | -151.09M▲ 30.1% | -235.76M▼ 56.0% | -197.53M▲ 16.2% | -250.64M▲ 0% |
Net Margin % | - | - | - | -2204.65% | - | -1316.88% | - |
Net Income Growth % | - | -3481.54% | 43.39% | 30.12% | -56.04% | 16.21% | -11.97% |
Net Income (Continuing) | -10.66M | -381.9M | -216.21M | -151.09M | -235.76M | -197.53M | -250.64M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.08▲ 0% | -4.24▼ 5356.9% | -2.31▲ 45.5% | -1.57▲ 32.0% | -2.06▼ 31.2% | -1.46▲ 29.1% | -1.63▲ 0% |
EPS Growth % | - | -5356.89% | 45.52% | 32.03% | -31.21% | 29.13% | 1.66% |
EPS (Basic) | -0.08 | -4.24 | -2.31 | -1.57 | -2.06 | -1.46 | - |
Diluted Shares Outstanding | 70.89M | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M | 153.55M |
Basic Shares Outstanding | 70.89M | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M | 153.55M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
CNTA Balance Sheet
Centessa Pharmaceuticals plc (CNTA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 11.16M | 628.77M | 437.75M | 315.09M | 536.41M | 367.88M | 348.68M |
Cash & Short-Term Investments | 7.23M | 595.08M | 393.64M | 256.55M | 482.18M | 294.58M | 276.59M |
Cash Only | 7.23M | 595.08M | 393.64M | 128.03M | 383.22M | 61.3M | 62.43M |
Short-Term Investments | 0 | 0 | 0 | 128.52M | 98.96M | 233.28M | 214.16M |
Accounts Receivable | 0 | 16.81M | 26.72M | 39.15M | 45.3M | 0 | 0 |
Days Sales Outstanding | - | - | - | 2.09K | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 3.93M | 993K | 3.27M | 1.62M | 1.78M | 73.3M | 72.09M |
Total Non-Current Assets | 552K | 861K | 6.56M | 45.15M | 40.39M | 319.62M | 293.08M |
Property, Plant & Equipment | 0 | 162K | 1.17M | 12.95M | 11.76M | 10.85M | 10.52M |
Fixed Asset Turnover | - | - | - | 0.53x | - | 1.38x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 282.55M | 795.9M |
Other Non-Current Assets | 552K | 699K | 1.88M | 2.55M | 2.05M | 1.44M | 1.28M |
Total Assets | 11.72M▲ 0% | 629.63M▲ 5273.7% | 444.31M▼ 29.4% | 360.25M▼ 18.9% | 576.8M▲ 60.1% | 687.5M▲ 19.2% | 641.76M▲ 0% |
Asset Turnover | - | - | - | 0.02x | - | 0.02x | 0.00x |
Asset Growth % | - | 5273.69% | -29.43% | -18.92% | 60.11% | 19.19% | 37.69% |
Total Current Liabilities | 8.62M | 24.64M | 38.34M | 39.38M | 58M | 42.94M | 36.57M |
Accounts Payable | 1.03M | 8.06M | 13.84M | 11.81M | 7.14M | 7.58M | 10.66M |
Days Payables Outstanding | - | - | - | - | - | - | 12.47K |
Short-Term Debt | 5.63M | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 922K | 4.97M | 7.95M | 839K | 10.18M | 35.35M | 25.92M |
Current Ratio | 1.30x | 25.52x | 11.42x | 8.00x | 9.25x | 8.57x | 9.53x |
Quick Ratio | 1.30x | 25.52x | 11.42x | 8.00x | 9.25x | 8.57x | 9.53x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 113.44M | 69.8M | 84.62M | 117.25M | 117.7M | 117.84M |
Long-Term Debt | 0 | 75.7M | 69.8M | 75.7M | 108.94M | 7.57M | 7.37M |
Capital Lease Obligations | 0 | 0 | 0 | 8.89M | 8.29M | 0 | 15.7M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 37.74M | 0 | 29K | 29K | 110.12M | 110.47M |
Total Liabilities | 8.62M | 138.08M | 108.14M | 124M | 175.25M | 160.63M | 154.41M |
Total Debt | 5.63M | 75.7M | 69.8M | 84.59M | 117.23M | 7.57M | 7.37M |
Net Debt | -1.6M | -519.38M | -323.84M | -43.44M | -266M | -53.73M | -55.06M |
Debt / Equity | 1.82x | 0.15x | 0.21x | 0.36x | 0.29x | 0.01x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.21x |
Interest Coverage | -27.21x | -54.67x | -28.81x | -16.78x | -22.08x | -18.12x | -23.48x |
Total Equity | 3.1M▲ 0% | 491.55M▲ 15766.8% | 336.17M▼ 31.6% | 236.24M▼ 29.7% | 401.55M▲ 70.0% | 526.86M▲ 31.2% | 487.35M▲ 0% |
Equity Growth % | - | 15766.82% | -31.61% | -29.72% | 69.97% | 31.21% | 38% |
Book Value per Share | 0.04 | 5.46 | 3.60 | 2.46 | 3.51 | 3.88 | 3.17 |
Total Shareholders' Equity | 3.1M | 491.55M | 336.17M | 236.24M | 401.55M | 526.86M | 487.35M |
Common Stock | 25.55M | 252K | 265K | 273K | 359K | 405K | 419K |
Retained Earnings | -23.84M | -385.65M | -601.86M | -752.95M | -988.7M | -1.19B | -1.27B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 572K | 688K | -1.5M | 1.49M | 4.21M | 2.71M | 1.41M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CNTA Cash Flow Statement
Centessa Pharmaceuticals plc (CNTA) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -10.63M | -136.14M | -200.55M | -160.34M | -142.06M | -193.82M | -208.79M |
Operating CF Margin % | - | - | - | -2339.73% | - | -1292.11% | - |
Operating CF Growth % | - | -1180.73% | -47.31% | 20.05% | 11.4% | -36.44% | -184.51% |
Net Income | -10.66M | -381.85M | -216.21M | -151.09M | -235.76M | -197.53M | -250.64M |
Depreciation & Amortization | 0 | 33.99K | 131K | 810K | 942K | 921K | 943K |
Stock-Based Compensation | 336K | 0 | 24.96M | 29.39M | 33.55M | 30.96M | 33.64M |
Deferred Taxes | 0 | 0 | -2.86M | -26.63M | 2.65M | 2.51M | 2.34M |
Other Non-Cash Items | 186K | 251.06M | -3.75M | 6.03M | 34.46M | 20.56M | 23.37M |
Working Capital Changes | -489K | -5.38M | -2.83M | -18.86M | 22.1M | -51.24M | -18.46M |
Change in Receivables | -1.46M | -6.72M | -11.71M | 0 | -6.6M | 2.91M | 3.59M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -49K | 0 | 6.35M | -2.73M | -4.58M | 2.96M | 5.41M |
Cash from Investing | 0 | 63.25M | -931K | -127M | 31.27M | -418.53M | -153.44M |
Capital Expenditures | 0 | -185.98K | -1.14M | -169K | -34K | -371K | -371K |
CapEx % of Revenue | - | - | - | 2.47% | - | 2.47% | - |
Acquisitions | 0 | 63.43M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 206K | 0 | 0 | 0 | -75.09M |
Cash from Financing | 1.36M | 660.07M | 457K | 21.12M | 364.75M | 291.53M | 318.91M |
Debt Issued (Net) | 1.36M | 73.64M | 0 | 0 | -762K | 0 | 0 |
Equity Issued (Net) | 0 | 586.43M | 0 | 20.81M | 359.61M | 0 | 49.01M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -12K | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1K | 0 | 457K | 310K | 5.91M | 291.53M | 269.89M |
Net Change in Cash | -9.34M▲ 0% | 590.08M▲ 6415.7% | -201.44M▼ 134.1% | -265.61M▼ 31.9% | 255.19M▲ 196.1% | -321.27M▼ 225.9% | -42.07M▲ 0% |
Free Cash Flow | -10.63M▲ 0% | -136.33M▼ 1182.5% | -201.68M▼ 47.9% | -160.51M▲ 20.4% | -142.09M▲ 11.5% | -194.19M▼ 36.7% | -209.17M▲ 0% |
FCF Margin % | - | - | - | -2342.2% | - | -1294.59% | - |
FCF Growth % | - | -1182.48% | -47.94% | 20.41% | 11.48% | -36.67% | -29.08% |
FCF per Share | -0.15 | -1.51 | -2.16 | -1.67 | -1.24 | -1.43 | -1.36 |
FCF Conversion (FCF/Net Income) | 1.00x | 0.36x | 0.93x | 1.06x | 0.60x | 0.98x | 0.83x |
Interest Paid | 0 | 0 | 7.28M | 9.91M | 10.09M | 0 | 5.24M |
Taxes Paid | 0 | 0 | 1.3M | 2.94M | 82K | 0 | 1.1M |
CNTA Key Ratios
Centessa Pharmaceuticals plc (CNTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -154.41% | -52.24% | -52.79% | -73.93% | -42.55% | -60.37% |
| Return on Invested Capital (ROIC) | - | -1291.66% | -125.25% | -91.85% | -51.18% | -45.48% |
| Gross Margin | - | - | 100% | - | 100% | - |
| Net Margin | - | - | -2204.65% | - | -1316.88% | - |
| Debt / Equity | 0.15x | 0.21x | 0.36x | 0.29x | 0.01x | 0.02x |
| Interest Coverage | -54.67x | -28.81x | -16.78x | -22.08x | -18.12x | -23.48x |
| FCF Conversion | 0.36x | 0.93x | 1.06x | 0.60x | 0.98x | 0.83x |
| Revenue Growth | - | - | - | -100% | - | -100% |
Related:CNTA Dividend History·CNTA Revenue History·CNTA Price History·CNTA P/E History·CNTA Financial Ratios·CNTA Institutional Holders
CNTA SEC Filings & Documents
Centessa Pharmaceuticals plc (CNTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
CNTA Frequently Asked Questions
Centessa Pharmaceuticals plc (CNTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Centessa Pharmaceuticals plc (CNTA) reported $15.0M in revenue for fiscal year 2025.
Centessa Pharmaceuticals plc (CNTA) grew revenue by 0.0% over the past year. Growth has been modest.
Centessa Pharmaceuticals plc (CNTA) reported a net loss of $250.6M for fiscal year 2025.
Dividend & Returns
Centessa Pharmaceuticals plc (CNTA) has a return on equity (ROE) of -42.6%. Negative ROE indicates the company is unprofitable.
Centessa Pharmaceuticals plc (CNTA) had negative free cash flow of $209.2M in fiscal year 2025, likely due to heavy capital investments.